Elaine Handcock
Psychiatric/Mental Health · New Orleans, LANPI 1033885207
Payments from drug & device makers
Across 136 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$556
- Alkermes, Inc.$446
- Johnson & Johnson$384
- Teva Pharmaceuticals USA, Inc.$277
- Neurocrine Biosciences, Inc.$240
- Otsuka America Pharmaceutical, Inc.$235
- plus $484 from 8 others
What the payments were for
- Food & beverage$2,621100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $556 |
| Alkermes, Inc. | 24 | $446 |
| Johnson & Johnson | 21 | $384 |
| Teva Pharmaceuticals USA, Inc. | 15 | $277 |
| Neurocrine Biosciences, Inc. | 10 | $240 |
| Otsuka America Pharmaceutical, Inc. | 13 | $235 |
| Vanda Pharmaceuticals Inc. | 5 | $121 |
| Indivior Inc. | 4 | $101 |
| Lundbeck LLC | 5 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Noven Therapeutics, LLC | 1 | $18 |
| Exact Sciences | 1 | $16 |
How this compares
$2,621 in reported general payments places this provider in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 31 | $209,001 |
| IngrezzaValbenazine Tosylate | 23 | $188,061 |
| Invega SustennaPaliperidone Palmitate | 55 | $151,479 |
| VraylarCariprazine Hcl | 92 | $133,918 |
| AristadaAripiprazole Lauroxil | 14 | $34,774 |
| RexultiBrexpiprazole | 11 | $15,155 |
| Aripiprazole | 65 | $5,861 |
| Paliperidone ErPaliperidone | 30 | $3,791 |
| Quetiapine Fumarate | 265 | $3,429 |
| Asenapine Maleate | 12 | $3,176 |
| Oxcarbazepine | 98 | $2,593 |
| Ziprasidone Hcl | 51 | $2,540 |
| Olanzapine | 98 | $2,119 |
| Risperidone | 116 | $2,052 |
| Mirtazapine | 120 | $1,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $277 | $209,00131 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $240 | $188,06123 claims |
| Johnson & JohnsonInvega Sustenna | $384 | $151,47955 claims |
| AbbVieVraylar | $556 | $133,91892 claims |
| Alkermes, Inc.Aristada | $446 | $34,77414 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $235 | $15,15511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in New Orleans
- Kelly RobinsonNew Orleans$23K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.